



FL1/68 2004 / 002685



INVESTOR IN PEOPLE

The Patent Office

Concept House

Cardiff Road

Newport

South Wales

NP10 8Q

QVIPO

REC'D 13 JUL 2004

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

Dated 7 July 2004

Andrew Garsley

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

 Cardiff Road
 Newport
 South Wales
 NP10 8QQ

1. Your reference

SMK/LP6150171

2. Patent application number

(The Patent Office will fill in this part)

24 JUN 2003

0314699.0

3. Full name, address and postcode of the or of each applicant (underline all surnames)

 Plant Bioscience Limited
 Norwich Research Park
 Colney Lane
 Norwich, Norfolk NR4 7UH
 UNITED KINGDOM

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

7489982001

4. Title of the invention

Detection System

5. Name of your agent (if you have one)

MEWBURN ELLIS

 "Address for service" in the United Kingdom
 to which all correspondence should be sent
 (including the postcode)

 York House
 23 Kingsway
 London WC2B 6HP

Patents ADP number (if you know it)

109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if)

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 13

Claim(s)

CF

Abstract

Drawing(s)

4 + 4

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Simon M Kremer

Date

24 June 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

SIMON M KREMER

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Detection SystemTechnical Field

5 The present invention relates to methods and materials for screening for compounds which have antibiotic activity. It further relates to methods for generating microorganisms having utility in screening, tools which can be generally used in such methods, the microorganisms themselves, and detection methods employing the
10 microorganisms.

BACKGROUND ART

15 There is an ongoing requirement for novel compounds that have antibiotic activity, for instance to counteract the problem of drug resistance. Methods for screening potential sources of antibiotic that have been used in the prior art include those which are based on particular 'indicator' or 'reporter' strains of bacteria.
20 A *vanHp*-cat fusion (regulated by *VanS/VanR* - see Ulijasz et al. (1996) was used by Lai and Kirsch (1996) to assay more than 6,800 compound for induction of *vanHp* in *Enterococcus faecium*.

25 WO 01/92559 (Plant Bioscience Limited) discloses a system in which heterologous reporter genes are used to detect the induction by antibiotics of multi-component cell wall responsive signal transduction systems. This is exemplified by *inter alia* *CseB\c* (regulates the *sigE* promoter), and *Van S\R* (regulates the *vanH* promoter).

30 WO 03/012128 (Plant Bioscience Limited) discloses a *Streptomyces coelicolor* based system in which heterologous reporter genes are used to detect the induction by antibiotics of a promoter from the *vanSREFHAX* cluster.

35

DISCLOSURE OF THE INVENTION

The present inventors have devised a novel system to provide a screen for cell wall-specific antibiotics. Unlike systems of the

prior art, this does not rely on the expression of a heterologous reporter gene in order to detect antibiotic activity. In embodiments of the invention, the inventors provide a "drug dependent" bacterial mutant strain that can only grow in the 5 presence of glycopeptides (such as vancomycin) that act as inducers of the *van* genes. Thus the presence of such antibiotics is readily and robustly detected by viability of the strain.

As a test system, the inventors have demonstrated that the 10 activation of *vanF* and *vanHAX* genes of *Streptomyces coelicolor* can compensate for the loss of activity in *femX* null mutants (note the equivalent gene designations in the *S. coelicolor* genome sequence (www.sanger.ac.uk/Projects/S_coelicolor/) are as follows: *vanF* = SCO3593; *vanH* = SCO3594; *vanA* = SCO3595; *vanX* = SCO3596; *femX* = 15 SCO3904).

Briefly, although not wishing to be bound by any particular mechanism or underlying specificity, it is understood that when expressed in active form, FemX adds a single cross-bridge glycine 20 to the stem pentapeptide of *S. coelicolor* cell wall precursors (Fig. 1). Because transpeptidation of this cross-bridge (Fig. 2) is essential for mature cell wall formation, FemX is an essential protein under 'normal' conditions. However, through the action of VanHAX enzymes, induction of the *van* genes remodels cell wall 25 precursors such that the stem pentapeptide terminates D-ala-D-lac instead of D-ala-D-ala (not shown) and this can also be subject to transpeptidation (Fig. 3). *S. coelicolor* FemX cannot recognise precursors terminating D-ala-D-lac; instead the *van* cluster encodes a FemX homologue, VanF, which can recognise precursors terminating 30 D-ala-D-lac as a substrate, and is therefore able to add the single glycine cross-bridge (Fig. 1).

Irrespective of the precise specificity, it can be seen from the disclosure herein that as a consequence, *femX* is non-essential 35 provided that *vanF* is expressed, and *femX* null mutants are viable in the presence of vancomycin or other inducers of the *van* genes, but die in the absence of such inducers (Fig. 4). This creates a drug-dependent strain that can only grow in the presence of *van* gene inducers (Fig. 4).

Thus in a first aspect of the invention there is disclosed a method of detecting an activity of a glycopeptide, such as an antibiotic, in a sample, the method comprising the steps of:

- 5 (a) providing a microorganism in which a first endogenous gene encoding peptidyltransferase activity is inactivated, which activity is necessary for growth of the microorganism, and which activity can be complemented by a second, different, peptidyltransferase, which second peptidyltransferase is inducible in the microorganism by the presence of the antibiotic,
- 10 (b) contacting the sample with the microorganism,
- (c) observing the microorganism for growth, wherein growth of the microorganism is correlated with the presence of the antibiotic.

15

The term "antibiotic" is used broadly in this aspect to include glycopeptidic compounds (natural, semi-synthetic or synthetic), which have the potential to inhibit or kill (susceptible) microorganisms generally by interfering with the physical integrity

20 of the cell envelope.

The precise specificity of the screen will depend on the specificity of induction of the second peptidyltransferase. In preferred embodiments of the invention (such as those based on

25 inactivation of FemX and the induction and activity of VanF), it is particularly effective for the detection of glycopeptide compounds such as cell wall-specific antibiotics that have the potential to induce the van genes - these include ristocetin and vancomycin.

30 By "observing" is meant ascertaining by any means (directly or indirectly) the growth or failure of growth of the microorganism.

The activity detected may be correlated with the presence or absence of an antibiotic, or putative antibiotic, in the sample in

35 a qualitative manner. Alternatively it may be used to make a quantitative assessment.

Some particular embodiments and aspects will now be discussed in more detail.

Samples may be selected from any suitable source. In particular, samples may be selected from culture supernatants and extracts from soil isolates, compounds produced by chemical synthesis including 5 combinatorial chemistry; and compounds produced by combinatorial biosynthesis.

The assay may use any suitable species of bacteria. Preferably the assay uses an actinomycete such as a strain of *Streptomyces* e.g. *S. 10 coelicolor* or *S. avermetilis*.

One preferred bacterium is M600, which is a plasmid-free derivative of wild-type *S. coelicolor* A3(2).

15 In addition, it may be preferred to use strains in which enzymes which may otherwise degrade glycopeptidic antibiotics (thereby reducing the sensitivity of the assay) have been inactivated.

20 In preferred embodiments the second peptidyltransferase will also be endogenous, although if it is not present, and if desired, the gene encoding it (and any ancillary enzymes preferred or required) could be introduced into it.

25 In preferred embodiments the peptidyltransferase activity is nonribosomal and operates on a substrate in the cell involved in cross-bridge formation of the microorganism cell wall.

30 Preferably the substrate is a stem pentapeptide cell wall precursor, and the peptidyltransferase adds a single glycine to it which can form a cross-bridge through D-ala transpeptidation.

35 In preferred embodiments the first peptidyltransferase acts on a stem pentapeptide substrate which terminates D-ala-D-ala e.g. the FemX polypeptide as described herein.

Regarding the second peptidyltransferase, this may likewise add a single glycine to a stem pentapeptide substrate which can form a cross-bridge through D-ala transpeptidation.

In one embodiment the presence of the antibiotic in the sample may induce additional enzymes which modify stem pentapeptide cell wall precursors such as to provide a substrate for the second peptidyltransferase. The additional enzymes may be present in the 5 same genomic cluster as the second peptidyltransferase. They may, for example, be the VanHAX enzymes as described herein which modify the stem pentapeptide substrate from a terminal D-ala-D-ala to a terminal D-ala-D-lac which can be acted on by the VanF polypeptide.

10 However where the second peptidyltransferase is capable of using the same substrate as the first peptidyltransferase, then there is no need to ensure that additional enzymes are present (whether endogenously or otherwise) or induced.

15 In another aspect of the invention there is provided a process of producing a microorganism, which may be used in any of the methods of the invention disclosed herein e.g. detection of antibiotics, which process comprises inactivating in the microorganism a first 20 endogenous gene encoding peptidyltransferase activity, wherein said activity is necessary for growth of the microorganism, and wherein said activity can be substituted by a second, different, peptidyltransferase, which second peptidyltransferase is 25 inducible in the microorganism by the presence of an antibiotic.

"Inactivation" in the various aspects of the invention includes disruption by any means e.g. deleting all or part of the gene, or introducing a lesion therein.

30 Generally speaking, those skilled in the art are well able to construct vectors and design protocols for gene inactivation, for example by mutagenesis. For further details see, for example, *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et 35 al., 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Current Protocols*

in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. The disclosures of Sambrook et al. and Ausubel et al. are incorporated herein by reference.

5 Any of the various preferred embodiments of the invention discussed in relation to the first aspect of the invention are applicable here also.

For embodiments in which the bacterium is a *Streptomyces* strain, 10 reference is also made to Hopwood, D.A., Bibb, M.J., Chater, K.F., Kieser, T., Bruton, C.J., Kieser, H.M., Lydiate, D.J., Smith, C.P., Ward, J.M., and Schrempf, H. (1985) "Genetic Manipulation of *Streptomyces*: A Laboratory Manual". Norwich: The John Innes Foundation and Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. 15 F., and Hopwood, D. A. (2000). "Practical *Streptomyces* Genetics". The John Innes Foundation, Norwich.

In a preferred embodiment the first endogenous gene encoding 20 peptidyltransferase activity is inactivated by introducing therein a heterologous marker sequence. This may be achieved by use of flanking sequences which are present in the first peptidyltransferase.

A preferred marker sequence is an apramycin resistance cassette 25 (apr) e.g. isolated from pIJ773 (available from PBL) by EcoRI/HindIII digestion.

The inactivation process may or may not be followed by further 30 manipulations to remove the marker sequence.

In a further aspect there is provided a microorganism, which may be used in any of the methods of the invention disclosed herein e.g. detection of antibiotics,

35 wherein the microorganism is characterised in that it includes

a first endogenous gene encoding peptidyltransferase activity which is inactivated, which activity is necessary for growth of the microorganism, and which activity can be substituted by a second, different, peptidyltransferase, which second

peptidyltransferase is inducible in the microorganism by the presence of the antibiotic.

In further aspects of the present invention there are provided systems for detecting an activity of an antibiotic in a sample comprising: (a) a mutant microorganism as described above, (b) means for detecting the viability of the microorganism in the presence of the antibiotic.

Also embraced within the scope of the present invention are kits for performing the various aspects of the invention. For instance a kit suitable for use in the first aspect may comprise a preparation of the microorganism, plus further means for carrying out the contact or observation steps e.g. buffers.

Naturally the methods and systems of the invention described above could be used as a primary screen, with further screens (e.g. based on antibiosis of target organisms, which may be different species to the screening microorganism) being employed to further exclude compounds not having the desired activity.

In another aspect of the invention there is provided a process of producing an isolated antibiotic which affects cell integrity, which method comprises the steps of:

(a) performing a method of the invention as described above such as to identify the activity of the antibiotic in a sample,

(b) isolating the antibiotic from the sample.

Optionally the process is preceded by the step of providing a mutant microorganism as described above.

The invention will now be further described with reference to the following non-limiting Figures and Examples. Other embodiments of the invention will occur to those skilled in the art in the light of these.

FIGURES

Figure 1. FemX can add the single gly cross-bridge to stem

pentapeptides terminating D-ala-D-ala, but not to stem pentapeptides terminating D-ala-D-lac. VanF can add the single gly cross-bridge to the stem pentapeptides terminating D-ala-D-lac.

5 Figure 2. The enzyme transpeptidase crosslinks adjacent polysaccharide chains through their peptide side chains. The transpeptidase cleaves off the terminal alanine, and joins the remainder to a glycine crossbridge from an adjacent polysaccharide chain.

10 Figure 3. The enzyme transpeptidase catalyses essentially the same reaction as in Figure 2 when the cell wall precursors terminate D-ala-D-lac. In this case, the transpeptidase cleaves off the terminal D-lac, and joins the remainder to a glycine crossbridge
15 from an adjacent polysaccharide chain.

Figure 4. *femX* is non-essential provided that *vanF* is expressed. Therefore, *femX* null mutants only grow in the presence of vancomycin or other inducers of the *van* genes, but die in the
20 absence of such inducers. In other words, *femX* null mutants are drug-dependent strain that can only grow in the presence of *van* gene inducers.

Table 1 summarises the results of the experiment described in
25 Example 2, in which 13 antibiotics were tested for their effects on the growth of the test strain.

Table 2 shows a sensitivity test using vancomycin.

30 EXAMPLES

Example 1. Creation of J3130, a 'drug-dependent' *Streptomyces coelicolor* strain unable to grow in the absence of inducers of the *van* gene cluster

35

Replacement of femX (=SCO3904) on cosmid H24.

The apramycin resistance cassette (*apr*) was isolated from pIJ773 (available from PBL) by EcoRI/HindIII digestion, gel purified and

then amplified by PCR using the forward *femX* primer (5'-
ACCCATGGGGACACACCAGCCGAGGAGCGCCCGAATGATTCCGGGATCCGTCGACC-3') and
the reverse *femX* primer (5'-
GCTGTCAGAGGTGCGGATCGGGATGGCGGTGCGGTATGTAGGCTGGAGCTGCTTC-3'). The
5 PCR product (the *apr* cassette with *femX* flanking DNA) was then gel
purified and eluted in 20 μ l autoclaved distilled water.

Electrocompetent cells of *E. coli* strain BW25113 (Datsenko and
Wanner, 2000) carrying pIJ790 (available from PBL) and cosmid H24
10 (Redenbach et al., 1996; available from the John Innes Centre) were
prepared as described (Gust et al, 2003) and 50 μ l cells were
electroporated with 300 ng purified PCR product in a 0.2 cm ice-
cold electroporation cuvette using a Bio-Rad gene Pulser II set to
200 Ω , 25 μ F and 2.5 Kv. Ice-cold LB (Kieser et al, 2000) (1 ml)
15 was immediately added to shocked cells followed by incubation,
shaking, at 37°C for 1 hour. Cells were harvested by brief
centrifugation, resuspended in 100 μ l LB and plated onto L-agar
plates (Kieser et al, 2000) containing kanamycin (50 μ g ml⁻¹) +
carbenicillin (100 μ g ml⁻¹) + apramycin (50 μ g ml⁻¹). After 18 hours
20 growth at 37°C cosmid DNA was isolated from transformant colonies
using alkaline lysis followed by phenol-chloroform extraction
(Sambrook et al, 1989) and the *femX*::*apr* disruption was confirmed
by restriction digestion with *Bam*HI and by PCR using a forward test
primer (5'-CCCGAGGAGCGCCCGAATG-3') and a reverse test primer (5'-
25 GGGGATGGCGGTGCGGTCA-3') which anneal to DNA sequences either side
of the disrupted *femX* gene. The *apr* cassette contains a unique
*Bam*HI site not present in the *femX* gene such that digestion of wild
type cosmid DNA gives a different restriction pattern after
separation on an agarose gel compared to cosmid DNA containing the
30 *apr* disrupted *femX* gene. In addition the *apr* cassette differs in
size to the *femX* gene such that PCR using *femX* flanking primers on
wild type and mutated cosmids will give products that are different
in size, again analysed by agarose gel electrophoresis.

35 Transfer of the mutagenised cosmid to *S. coelicolor*.

Mutagenised cosmid DNA was used to transform the *dam*, *dcm* strain
ET12567/pUZ8002 (available from the John Innes Centre) by
electroporation (as above) and introduced into *S. coelicolor* strain

M600 (available from the John Innes Centre) by conjugation (Gust *et al*, 2003). Apramycin-resistant (Apr^R) exconjugants were selected on SFM medium (Kieser *et al*, 2000) and screened for kanamycin sensitivity (Gust *et al*, 2003).

5

Isolation of double crossovers.

Spores isolated from Apr^R , kanamycin-resistant (Kan^R) colonies were plated onto SFM medium + apramycin ($50\mu\text{g ml}^{-1}$) + vancomycin ($10\mu\text{g ml}^{-1}$). In the presence of vancomycin, kanamycin-sensitive *femX* null mutant colonies were readily isolated, and one was designated J3130. However, *femX* mutants were unable to grow in the absence of vancomycin.

15 Example 2. Testing of the reporter strain

To see if growth of J3130 could be induced by control antibiotics known to target the cell envelope, spores of J3130 were spread on MMT medium (Kieser *et al*, 2000) and potential inducers were applied 20 on paper discs to the freshly spread plates. The results for 16 antibiotics are shown in Table 1. All of the glycopeptides tested (vancomycin, ristocetin, chloroeremomycin and A47934) induced a halo of growth around the paper disc. None of the other antibiotics tested, including many cell wall-specific non-glycopeptide antibiotics, induced growth of J3130.

25 Table 1 summarises the results of the assay for the antibiotics used. Thus, it is clear that the bioassay detects a wide variety of glycopeptide antibiotics, thereby allowing the system to act as a generic screen for glycopeptide antibiotics.

30 These results clearly show the utility of the system as a screen. For instance, an initial assessment of sensitivity demonstrated that 80 ng of vancomycin gives a positive reaction in the bioassay 35 (Table 2).

Example 3. Use of reporter strain in bioassay

In order to perform the assay of the invention, spores of J3130 are

spread on MMT medium at concentration of approximately 5×10^6 / 12cm² plate. Test compound is applied on paper discs to a number of freshly spread plates in parallel using a different concentration of the test compound in each plate. A halo of growth 5 indicates that the test compound is an inducer of the van genes.

References

10 Ausubel et al. eds., *Current Protocols in Molecular Biology*, Second Edition, John Wiley & Sons, 1992.

15 Datsenko, K.A., and Wanner, B.L. (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci USA* 97: 6640-6645.

20 Gust, B., Challis, G. L., Fowler, K., Kieser, T. and Chater, K. F. (2003). PCR-targeted *Streptomyces* gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin. *Proc. Natl. Acad. Sci. USA* 100: 1541-1546.

25 Lai, M.H., and Kirsch, D.R. (1996) Induction signals for vancomycin resistance encoded by the vanA gene cluster in *Enterococcus faecium*. *J Bacteriol.* 178: 1645-1648.

30 Redenbach, M, Kieser HM, Denapaite D, Eichner A, Cullum J, Kinashi H, Hopwood DA (1996) A set of ordered cosmids and a detailed genetic and physical map for the 8 Mb *Streptomyces coelicolor* A3(2) chromosome. *Mol Microbiol* 21: 77-96

35 Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.

Ulijasz, A.T., Grenader, A., and Weisblum, B. (1996) A vancomycin-inducible lacZ reporter system in *Bacillus subtilis*: induction by antibiotics that inhibit cell wall synthesis and by lysozyme. *J Bacteriol* 178: 6305-6309.

| Glycopeptides | Penicillins | Cephalosporins and other β -lactams | Peptides | Antibiotics that do not target the cell envelope at all |
|------------------|----------------|---|--------------|---|
| Vancomycin | ✓ Penicillin G | ✗ Cefaclor | ✗ Bacitracin | ✗ Novobiocin (target - DNA gyrase) |
| Ristocetin | ✓ Penicillin V | ✗ Cefadroxil | ✗ | Thiostrepton (target - the ribosome) |
| A47934 | ✓ Amoxycillin | ✗ Cephapirin | ✗ | Streptomycin (target - the ribosome) |
| Chloroeremomycin | ✓ Ampicillin | ✗ Cepharadine | ✗ | |

Table 1. 13 antibiotics known to target the cell envelope and three antibiotics that do not target the cell envelope were tested for their ability to induce growth of J3130 in the bioassay (✓ = induced a halo of growth; ✗ = did not induce a halo of growth).

| Amount of vancomycin μ g | Growth |
|------------------------------|--------|
| 10 | ✓ |
| 5 | ✓ |
| 2.5 | ✓ |
| 1.3 | ✓ |
| 0.6 | ✓ |
| 0.3 | ✓ |
| 0.15 | ✓ |
| 0.08 | ✓ |
| 0.04 | ✗ |
| 0.02 | ✗ |
| 0.01 | ✗ |
| 0.005 | ✗ |
| 0.002 | ✗ |
| 0.001 | ✗ |
| 0.0005 | ✗ |
| 0.0003 | ✗ |

Table 2. Two-fold dilution series test of vancomycin from 10 μ g on *femX* mutant (✓ = induced growth; ✗ = did not induce growth, in the bioassay).

Fig. 1

1/4




Fig. 2




Fig. 3





Fig. 4



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.